reason report
full year launch behind consum set drive
bottom line remain outperform believ
lower sequenc cost competit among custom
continu drive novaseq product upgrad cycl
complet first full year launch came slightli higher
pre-announce quarter revenu kept
conserv guid highlight earlier link novaseq
consum remain underappreci believ
driver growth though expect revenu ramp
smooth remain confid emerg instal base
still conserv guid consum pull-thru novaseq
increas pt higher growth rate assumpt
outer year
elast demand alreadi action time elast
matter near term though third way
novaseq launch alreadi see elast demand
play much line prior expect purchas
novaseq custom gain lower sequenc cost
near drive sampl demand deeper
sequenc applic rang whole genom liquid biopsi
believ time elast demand matter
lab pull-in sampl perform deeper sequenc
shift gear lower cost sequenc novaseq
ship novaseq guid instal
indic earlier compani ship novaseq
year quarter one-third custom continu
come desktop sequenc new sequenc higher
expect believ guid
novaseq instal remain conserv see high-throughput
custom choic buy instrument order compet
market new sequenc custom continu purchas
well given expand market
guid still conserv flow cell expect releas
quarter continu guid revenu growth y/i
ep seem conserv opinion
given see full year effect
high-throughput custom current upgrad novaseq
releas flow cell could attract custom wait
sidelin wari overal massiv throughput novaseq
provid hiseq user faster turnaround time take
hour run flow-cel could see new custom addit
look upgrad hiseq need
high amount capac denser flow cell model
estim previous
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu mm ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
rate share outperform price target view
custom compet race reduc sequenc cost
manifest novaseq order believ sequenc market number
sampl depth coverag expand dramat next year novaseq
drive signific reduct sequenc cost hiseq
novaseq flow cell novaseq set path reach research
grade genom longer term price beyond high throughput platform also
continu drive double-digit growth desktop system includ nextseq essenti
key high growth market includ non-invas pre-nat test nipt oncolog
continu domin sequenc market world-wide address market
size life scienc genet test reproduct health oncolog market
share revenu market share sequenc unit believ ilmn market
share accuraci throughput enterpris level servic product factor
continu keep custom bound despit custom consid higher
price still direct strong competit sight somewhat unbound market
believ continu domin next-gen sequenc keep drive sequenc cost
lower lead elast demand sampl deeper sequenc need
share current trade price-to-earnings consensu ep averag
life scienc tool lst group multipl longer compar high-
growth high-tech peer life scienc tool peer given somewhat unbound market
opportun major popul develop develop world
touch sequenc form test next year use dcf
analysi use beta long-term growth rate wacc arriv
price target believ long-term growth rate conserv
estim given sequenc repres somewhat unbound market opportun
opinion still applic continu explor beyond hereditari
somat test oncolog nipt diseas area
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report leerink partner estim
lower
slightli
sequenti line
normal season
dollar thousand except ep
estimate
servic revenu
revenu
compani report leerink partner estim
